Key facts
- This page summarizes Riley Charles Ennis's Form 3 filing for Freenome, Inc. (FRNM).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 27 Jul 2026, 20:48.
Riley Charles Ennis - 20 Jul 2026 Form 3 Insider Report for Freenome, Inc. (FRNM)
- Reporting relationship
- Chief Product Officer
- Issuer ticker
- FRNM
- Reported as of
- 20 Jul 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Thomas Fitzpatrick, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Riley Charles Ennis filed Form 3 for Freenome, Inc. (FRNM) on 27 Jul 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002142835
Primary reporting owner
Ennis Riley Charles
- Relationship
- Chief Product Officer
- Address
- C/O FREENOME, INC., 51 ASTOR PLACE, 10TH FLOOR, NEW YORK
- Signature
- /s/ Thomas Fitzpatrick, Attorney-in-Fact
- Signature date
- 27 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FRNM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,490,453
- Date
- 20 Jul 2026
- Ownership
- Direct
FRNM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 373,913
- Date
- 20 Jul 2026
- Ownership
- By Trust
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FRNM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 310,958
- Exercise price
- $4.85
- Footnotes
- F2
FRNM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 281,369
- Exercise price
- $15.91
- Footnotes
- F2, F6
FRNM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,082
- Exercise price
- $11.88
- Footnotes
- F3, F6
FRNM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 118,471
- Exercise price
- $18.24
- Footnotes
- F4, F6
FRNM
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 221,457
- Exercise price
- $14.00
- Footnotes
- F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Represents shares held by the Riley Ennis Irrevocable Trust dated 1/14/21. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Footnote F2
The shares subject to this option are fully vested.
Footnote F3
25% of the shares subject to this option shall vest and become exercisable on February 2, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F4
The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from February 16, 2024, subject to the Reporting Person's continued service on each such vesting date.
Footnote F5
25% of the shares subject to this option shall vest and become exercisable on February 15, 2026 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F6
This option was previously amended, pursuant to which the exercise price of the option will be automatically reduced to $8.45 upon the occurrence of certain events.
SEC remarks
Exhibit 24 - Power of Attorney